

Company Name: Linical Co., Ltd. Representative: Kazuhiro Hatano

Representative Director

TSE code: 2183

November 14, 2024

Notice Concerning a Revision of the Results Forecast

Linical Co., Ltd. (the Company) hereby informs that the Company has revised its consolidated results forecast for the fiscal year ending March 2025 (April 1, 2024 to March 31, 2025), which was announced on May 15, 2024, as follows.

 Revision of the consolidated results forecast for the fiscal year ending March 2025 (April 1, 2024 -March 31, 2025)

(Unit: million yen)

| | Sales | Operating profit | Ordinary profit | Net profit attributable to owners of the parent | Net profit per share |
|---|--------|------------------|--------------------|--|----------------------|
| Previously announced forecast (A) | 12,669 | 1,009 | 1,047 | 697 | 30.86 yen |
| Revised forecast (B) | 11,468 | 250 | 258 | 150 | 6.64 yen |
| Change (B-A) | △1,201 | △759 | △789 | △547 | |
| Change (%) | △9.5 | △75.2 | △75.4 | △78.5 | |
| (Reference) Results for the previous fiscal year (Fiscal year ended March 2024) | 12,307 | 725 | 790 | 338 | 14.98 yen |

2. Reason for the revision

The Company has revised the full-year consolidated results forecast announced on May 15, 2024 as above for the following reasons.

As for net sales, although sales in the United States exceeded expectations due to the steady progress of existing projects, the acquisition of new projects in Europe and Japan did not proceed as planned. As a result, we were unable to cover the decrease in sales due to the cancellation of projects in Japan. In addition, due to the large-scale medical strike that occurred in South Korea from February this year, progress of existing projects was delayed and negotiations on new projects failed. For these reasons, net sales through the second quarter were lower than initial

expectations. Although there are many new candidate projects in South Korea, if the medical strike is prolonged, there is a possibility of further impact on business results. In Europe and the United States, on the other hand, we are exerting global synergies in our sales activities, and we will strive to recover in Europe through the fourth quarter in addition to our favorable U.S. business.

In terms of expenses, we are reducing personnel expenses, including personnel adjustments, and reviewing SG & A expenses at all sites. However, operating profit is expected to be significantly lower than the previous forecast due to the significant impact of decreased sales in Japan and Asia.

For the above reasons, we expect full-year consolidated net sales of 11.46 billion yen, operating profit of 250 million yen, ordinary profit of 258 million yen and net profit attributable to owners of the parent of 150 million yen.

End

(Note)

- 1) The above forecast is based on information that the company has obtained at the present time and certain assumptions judged to be reasonable. Actual results may differ greatly from the forecast due to various factors.
- 2) This is a translation of the press release originally drafted in Japanese for the disclosure required in compliance with the TSE regulations.